Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05922202
Recruiting Observational

Influence of Frailty on Cardiovascular Events and Mortality in Patients With COPD.

NCT05922202 · tracked via the Priya Life Science Italy tracker
Sponsor
Azienda Ospedaliero-Universitaria di Modena
Phase
Observational
Started
2024-02-23
Last updated
2025-08-05

Condition(s) studied

Role of Frailty in COPD

Investigational drug(s) / intervention(s)

Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months

Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months: At 12 and 24 months of follow up, cardiovascular events (including hospital admissions), deaths due to cardiovascular disease, deaths due to all-cause, deaths due to COPD will be recorded in COPD outpatients group.

Study summary

Observational study on the influence of frailty on cardiovascular risk in COPD.

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with age ≥18 years, with diagnosis of COPD of at least 1 year, in stable condition, without acute exacerbation in the last 30 days and/or all-cause hospitalisation in the last 3 months * Smoking history of ≥ 10 pack/years * Diagnosis of COPD according to GOLD guidelines (www.goldcopd.org) * Individuals able to provide their written informed consent. Exclusion Criteria: * Concurrent diagnosis of interstitial lung disease * Presence of restrictive pattern on spirometry * No history of smoking habit * Individuals not able to provide their written informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Respiratory Unit - Hospital Policlinico Modena Modena Italy Recruiting

More Azienda Ospedaliero-Universitaria di Modena trials in Italy

Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients Recruiting
Psychosocial Intervention for Behavioral Symptoms in Hospitalized Patients With Dementia or Delirium Active, not recruiting
Colchicine Effect on Amyotrophic Lateral Sclerosis Patients Starting soon
Home Ultra-long Term EEG Monitoring for Rare Epilepsies and Developmental and Epileptic Encephalopathies Recruiting
Clinics and Epidemiology of Pituitary Diseases in Modena Area Population Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05922202 on ClinicalTrials.gov ↗ ← All trials in Italy